Literature DB >> 8464888

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

H Hock1, M Dorsch, U Kunzendorf, Z Qin, T Diamantstein, T Blankenstein.   

Abstract

Interleukin (IL)-2, IL-4, IL-7, tumor necrosis factor (TNF), or interferon-gamma (IFN-gamma) has been shown to be able to induce tumor rejection if produced locally by the tumor cells after gene transfer. To analyze whether the cellular rejection mechanisms are different or redundant we have expressed the cytokines in the same tumor cell line (J558L). Cell depletion experiments revealed that all cytokines required CD8+ T cells for complete long-term tumor eradication, although effective but transient host-dependent tumor suppression was also observed in the complete absence of CD8+ T cells. The transient tumor suppression induced by IL-2, IL-4, TNF, or IFN-gamma was also operative in nude and severe combined immunodeficient mice, whereas only tumor suppression induced by IL-7 was dependent on the presence of CD4+ T cells and was not evident in nude mice. The T-cell-independent effector arm of IL-2 and IFN-gamma but not IL-4 and TNF was mediated in part by natural killer cells. The transience of tumor suppression in the absence of T cells reflected loss of cytokine production in the case of TNF, IL-2, and IL-4 but not IFN-gamma. Immunohistologic analysis revealed all cytokine-producing tumors to be heavily infiltrated by macrophages. IL-4 and IL-7 tumors additionally contained eosinophils. The infiltration by T cells did not necessarily reflect their contribution to tumor rejection. Thus, the different cytokines activate heterogeneous transient tumor-suppressive mechanisms but always require CD8+ T cells for complete tumor rejection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464888      PMCID: PMC46178          DOI: 10.1073/pnas.90.7.2774

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.

Authors:  M P Colombo; A Modesti; G Parmiani; G Forni
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

2.  Suppression of tumor formation in vivo by expression of the JE gene in malignant cells.

Authors:  B J Rollins; M E Sunday
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

3.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

4.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.

Authors:  R I Tepper; R L Coffman; P Leder
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

5.  Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.

Authors:  W H McBride; J D Thacker; S Comora; J S Economou; D Kelley; D Hogge; S M Dubinett; G J Dougherty
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  Interleukin-4-mediated tumor suppression in nude mice involves interferon-gamma.

Authors:  C Platzer; G Richter; K Uberla; H Hock; T Diamantstein; T Blankenstein
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

7.  Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas.

Authors:  P Bertrand; N Girard; B Delpech; C Duval; J d'Anjou; J P Dauce
Journal:  Int J Cancer       Date:  1992-08-19       Impact factor: 7.396

8.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

Authors:  P T Golumbek; A J Lazenby; H I Levitsky; L M Jaffee; H Karasuyama; M Baker; D M Pardoll
Journal:  Science       Date:  1991-11-01       Impact factor: 47.728

9.  Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma.

Authors:  B Bottazzi; S Walter; D Govoni; F Colotta; A Mantovani
Journal:  J Immunol       Date:  1992-02-15       Impact factor: 5.422

10.  Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression.

Authors:  M Dorsch; H Hock; U Kunzendorf; T Diamantstein; T Blankenstein
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

View more
  49 in total

Review 1.  Therapeutic genes for cancer gene therapy.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

Review 2.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 3.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 4.  Gene therapy in pediatric oncology.

Authors:  E Benaim; B P Sorrentino
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Authors:  Thomas Kammertoens; Christian Friese; Ainhoa Arina; Christian Idel; Dana Briesemeister; Michael Rothe; Andranik Ivanov; Anna Szymborska; Giannino Patone; Severine Kunz; Daniel Sommermeyer; Boris Engels; Matthias Leisegang; Ana Textor; Hans Joerg Fehling; Marcus Fruttiger; Michael Lohoff; Andreas Herrmann; Hua Yu; Ralph Weichselbaum; Wolfgang Uckert; Norbert Hübner; Holger Gerhardt; Dieter Beule; Hans Schreiber; Thomas Blankenstein
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

Review 6.  Renal transplant fine needle aspiration and cytokine gene expression.

Authors:  C C Nast
Journal:  Pediatr Nephrol       Date:  1995       Impact factor: 3.714

7.  Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells.

Authors:  G Pecher; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

8.  Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection.

Authors:  Yi-Wei Li; Shuang-Jian Qiu; Jia Fan; Qiang Gao; Jian Zhou; Yong-Sheng Xiao; Yang Xu; Xiao-Ying Wang; Jian Sun; Xiao-Wu Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-10       Impact factor: 4.553

9.  Ectopic expression of CCL19 impairs alloimmune response in mice.

Authors:  Stefan Krautwald; Ekkehard Ziegler; Reinhold Förster; Lars Ohl; Kerstin Amann; Ulrich Kunzendorf
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

10.  Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice.

Authors:  J M Tufariello; S Cho; M S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.